29 August 2024FeaturesAmericasKristen Lovin & Niall Frizzell of Keker, Van Nest & Peters

Litigation implications of the USPTO’s terminal disclaimer proposal

If adopted, the pending rule would reshape litigation strategy and offer patent defendants a valuable tool, say Kristen Lovin and Niall Frizzell of Keker, Van Nest & Peters

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

More features

Masimo keeps $634m smartwatch award and moves to appeal

Why is 2026 already a record year for M&A activity?

Goodwin launches San Diego office with senior life sciences hire

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer

IP Federation elects Philips licensing leader as new president

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

Exelixis opens two-front patent dispute over Cabometyx copies

Litigation implications of the USPTO’s terminal disclaimer proposal

More on this story

Editor's picks

Editor's picks

More features